Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You Said:
So can they update you or any of their other mouth pieces as to who - what researchers are working on a vaccine and what exactly they're doing RIGHT NOW specifically at Texas A&M?
1. I DON"T work for ENZC.
2. Whatever ANY BIOTECH Company is doing it is not going to be shared with the public until it is in the best interest of the company.
Who is on the research team so we can get some credentials and besides computer generated IT , is any one actually working on anything hands on that would lead to the development of an anti-viral drug or treatment capable of eliminating 95% ++ of COVID and AIDS virus as some have stated?
Who We Are
Charles S. Cotropia – CEO and Chairman of the Board
Mr. Cotropia holds a Bachelor of Science degree with honors in Aerospace Engineering from the University of Texas at Austin and a Juris Doctorate Degree from Cornell University. He is a member of the Texas Bar Association and has served as a Member of the Board of Directors of the Dallas Bar Association. He is licensed to practice law in Federal District and Texas State courts and before the United States Patent and Trademark Office.
Prior to his current position as CEO and Board Chairman of Enzolytics, Mr. Cotropia served as CEO of BioClonetics Immunotherapeutics, Inc. from its formation in 2009 until the recent acquisition of BioClonetics by Enzolytics.
From 1973 until 2015, Mr. Cotropia also practiced law, specializing in the intellectual property field. During that period, he served as a partner in the law firm Sidley Austin LLP in its Dallas office. As an intellectual property lawyer for over 43 years, he handled cases in the areas of patents, trademarks, trade dress, unfair competition and copyrights. As a lawyer, he served as lead counsel in patent, trademark, trade dress and copyright disputes litigated in Federal and State Courts and the United States Patent and Trademark Office. During his legal career, Mr. Cotropia represented clients in the diverse areas of biotech, aerospace, electronics, the Internet, commercial products and oil and gas equipment and processes.
Harry H. Zhabilov – CSO and Director
Mr. Zhabilov is Chief Scientific Officer of Enzolytics, Inc. He also serves as President & Chief Scientific Officer at Immunotech Laboratories, Inc. He is a Member of American Institute of Chemical Engineers and Member of American Chemical Society. Mr. Zhabilov previously served as Executive Vice President at VG Life Sciences, Inc., Vice Chairman, Secretary & Chief Science Officer at International Technology Systems, Inc. and as Research Scientist at Bulgarian Academy of the Sciences.
Mr. Zhabilov holds a Master’s Degree from the University of Chemical Technology and Metallurgy in Sofia, Bulgaria. He is also a Member of American Chemical Society and a Member of American Institute of Chemical Engineers. Mr. Zhabilov served as Chief Scientific Officer for GXP Biopharm, Inc., and Vice President of Research and Development for Viral Genetics, Inc.
Mr. Zhabilov has extensive experience in protein isolation and purification in immunochemistry and biochemistry along with experience with therapeutic proteins used to treat HIV and cancer. Mr. Zhabilov also has experience in the preparation of applications for a nutraceutical compound/supplement submitted to the FDA. He is also the inventor named in several U.S. patents covering technology related to the immunotherapy of HIV and cancer and an immune enhancer based on the IPF (Inactivated Pepsin Fragment) platform. Mr. Zhabilov has also participated in the management of several clinical trials utilizing therapeutic proteins.
Joseph P. Cotropia, MD – Chief Medical Officer and Director
Dr. Cotropia holds a Medicine Degree from the Univ. of Texas Southwestern Medical School, a Master of Science Degree in Physiological Chemistry from the University of Wisconsin at Madison, Wis. and a Bachelor of Science Degree for the University of Texas at Austin, Texas.
He has taught as an Assistant Professor of Immunology at the University of Texas M.D. Anderson Hospital and Tumor Institute in Houston, Texas, served as in Internal Medicine Intern at Presbyterian Hospital Dallas, Texas and completed his internal medicine residency at the Central Texas Medical Foundation, Brackenridge Hospital in Austin, Texas.
Dr. Cotropia has worked previously at the M.D. Anderson Cancer Center and the Food and Drug Administration Center and the Food and Drug Administration Center for Biologics Evaluation and Research (CBER) where he had hands-on experience with immunotherapeutic biotechnology platforms directly related to monoclonal antibodies. Dr. Cotropia is the creator of the Company’s fully human anti-HIV monoclonal antibodies and the Company’s proprietary methodology for producing monoclonal antibodies targeting numerous infectious diseases.
He has clinical experience as a staff physician at the University of Pennsylvania, has worked in cell biology at the Center for Biologics Evaluation and Research Division at the Food and Drug Administration in Bethesda, Maryland and has further clinical experience as a physician at the University of Texas Health Center.
Gaurav Chandra, MD – Chief Operating Officer and Director
Dr. Gaurav Chandra has a Doctor of Medicine Degree from Albert Einstein College of Medicine, Montefiore, NY, a Bachelor of Medicine degree from Kasturba Medical College, Manipal India, and a Masters in Business Administration Degree from the University of Colorado, Denver, Colorado.
He is a trained surgeon with a Fellowship in Burn Surgery and Critical Care at the University of Colorado, Denver, Colorado. He has extensive experience in Clinical Research in Immunology and Infectious Diseases. His scientific contributions and advancements have been recognized globally. He also has vast experience with taking ideas all the way from basic research in the lab to clinical applications. His experience also extends to designing and conducting Pre-Clinical and Clinical Trials for Drug Development.
He brings experience in applying Artificial Intelligence to the field of biomedical therapeutic development and continues to lead the integration of Artificial Intelligence into the Company’s technology for the creation of the multiple potent therapeutic Monoclonal Antibodies.
He has global experience serving as a strategic advisor to senior executives of private equity firms, biopharma companies and healthcare systems to implement strategic goals.
Ronald Moss, MD – Scientific Advisor
Dr. Moss has a Doctor of Medicine Degree from the Chicago Medical School, Chicago, IL and a Bachelor of Arts degree from SUNY at Stony Brook, NY. His post graduate training includes courses at the American Association of Immunologists Advanced Immunology Course, HIV Primary Care Mini-Residency Program, Owen Clinic, University of California at San Diego; Allergy and Immunology Fellowship, Clinical Associate in Allergy and Clinical Immunology, Laboratory of Clinical Investigation, NIAID, National Institute of Health, Bethesda MD.
Dr. Moss completed his medical residency in Pediatrics (Research Track) and Assistant Clinical Institute at SUNY in Stony Brook Department of Pediatrics, Stony Brook, NY.
He serves on many corporate boards and has held officer positions in several biotech companies, including:
Adamis Pharmaceuticals, San Diego, CA, March 2017-Present, Chief Medical Officer
Ansun Biopharma Inc., San Diego, CA
Nexbio Inc, San Diego, CA
Vical Inc., San Diego, CA
Telos Pharmaceuticals, San Diego, CA
Merck & Co. Inc., West Point, PA
The Immune Response Corp., Carlsbad, CA.
He has also taught at the UCSD Medical Center, Division of Allergy/Immunology, as Associate Clinical Professor from 1994 to the present.
Repeating names and saying ""I believe them because they are doctors or chemical engineers" doesn't mean much to me.
That is how it works with ALL companies or do you get on the PHONE and CALL the CEO
I want to know if this thing is actually happening in my life time, or is this all preliminary chatter that has no time restraints.
That is our HOPE. WE know this is a risky investment however we accept the risk with what we know about the company based on our own RESEARCH.
I know some people don't like people who ask questions and want to trash talk them when they do, but that doesn't bother me as you all know. I'm used to those off the wall comments .
ASK ALL THE QUESTIONS you want however you may not like the ANSWERS
THE BOTTOM LINE IS ENZC HAS MADE TREMENDOUS PROGRESS IN THE LAST SIX (6) AND THE EXPECTATIONS FOR THEM TO SUCCEED HAS NEVER BEEN GREATER THAN NOW!!!
FDA is considering all possibilities by any means that can shut Covid-19 down or keep it in check. ENZC technology can certainly help in this process. It is only a matter of time when we find out just how involved we are either leading the charge or part of a collaboration with another company.
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-continues-important-work-support-medical-product-development-address
Our agency has had experience with evolving infectious diseases. Influenza vaccines and diagnostics are often modified each year to address the predicted predominant strains circulating globally. The agency has created and used regulatory processes that facilitate these updates. We will utilize our experience with influenza to help inform a path forward if SARS-CoV-2 variants emerge against which currently authorized vaccines are not sufficiently effective. Similarly, the FDA also has vast experience with HIV developing resistance to antiviral drugs and will follow regulatory pathways to quickly enable new antiviral drug development for resistant virus.
We have already been communicating with individual medical product sponsors to provide information as they evaluate the impact of COVID-19 variants on their products. And as part of our commitment to a public and transparent process, the FDA is developing guidances for diagnostic, therapeutic and vaccine developers to help guide ongoing medical product development.
For therapeutics, particularly virus-targeting monoclonal antibodies, we are considering approaches to help expedite drug development in this key area, including discussing appropriate regulatory flexibilities. We are aware that some of the neutralizing monoclonal antibodies that have been authorized or are under development are less effective against some of the COVID-19 variants that have emerged, and we are working with drug developers to accelerate the evaluation of new antibodies that could be effective against mutations.[/color] Relying on our growing experience with this class of drugs, our teams are discussing approaches to the generation and evaluation of pre-clinical, clinical and chemistry, manufacturing and controls data.
For authorized vaccines, our teams are currently deliberating and discussing the types of data needed to support changes in the composition of the vaccine, either through altering the existing vaccine or through the addition of new vaccine component(s), including how sponsors could demonstrate immune response to new variants through streamlined clinical programs that still gather the crucial data the FDA needs to demonstrate effectiveness, but can be executed quickly to gather this data. To be clear, while we continue to develop an understanding of and address any impact of variants on FDA-regulated products, at this time, available information suggests that the authorized vaccines remain effective in protecting the American public against currently circulating strains of COVID-19.
About ENZC CLINICAL TRIALS
Company begins process of identifying conserved/immutable target sites on SARS-CoV-2 (the CoronaVirus) and other developments
COLLEGE STATION, TX / ACCESSWIRE / February 1, 2021
In addition, the Company offers this update on its progress toward FDA approval of ENZC's licensed ITV-1 Immunotherapy treatment previously tested in human trials in Bulgaria. On April 29, 2019, Bulgaria, as a member of the European Medicines Agency (EMA), was recognized under the Mutual Recognition Agreement (MRA) between the FDA and European Union for medicinal products for human use subject to limitations. This allows drug inspectors to rely upon information from drug inspections conducted within countries recognized under the Treaty. The limitations stated on the U.S. Food & Drug Administration Website, listed as current as of 5/08/2020, read as follows:
"The capability determinations apply to routine surveillance inspections. In the future the following product and inspection types may be included in the coverage of the agreement, pending further consideration:
Vaccines for human use
Plasma derived pharmaceuticals
Investigational products (clinical trial material)
Veterinary products
Excluded from the MRA scope are: Advanced Therapy Medicinal Products (ATMPs), human blood, human plasma, human tissues and organs and veterinary immunologicals."
To establish the effect of this new directive on the Company, Company representatives visited Sofia, Bulgaria last month and met with the Executive Director of Bulgarian Drug Administration (BDA) to determine how this treaty affects the use of the Company's ITV-1 immunotherapy treatment which was successful in clinical trials completed in 2016. This meeting was followed by a meeting with a Clinical Research Organization, Clinic Design, in Sofia. The Company believes, and is currently reviewing the applicable information, that with the BDA recognition under the MRA and its membership in the European Medicines Agency (EMA), its Immunotherapy treatment should qualify for recognition by the FDA once the Clinical Trial process and Validation order have been completed. The Company has been informed that the inclusion of the BDA in the EMA restricted the permitting of our Treatment by the BDA and the permitting will now be done by the EMA for all the European Union. As a result, some, if not all of the clinical trials may need to be completed under the EMA standards. The company is evaluating the necessary steps and cost for the FDA submission under the Mutual Recognition Agreement between the FDA and EMA.
Based on this information, the Company took the following actions. On January 28th, a notice of default and termination was registered with the courts in Sofia of the Sub License Agreement issued to IMMB BG. The company has entered into negotiations with a supportive group in Bulgaria to form a new entity and enter a funding agreement to cover any new cost of clinical trials under EMA standards and permitting by the EMA. Strategically, the Company believes that the actions will be cost effective resulting in a significant advancement of the Company's therapeutic portfolio.
https://marketwirenews.com/news-releases/enzolytics-announces-the-discovery-of-seven-newly-id-7491922242125190.html
Enzolytics Finalizes Documentation with International Medical Partners, Ltd for Clinical Trials and Initial Production of ITV-1 Company Also Provides Update on Year End Reporting
As a team, the Company with IMPL is moving forward to complete the initial production and certification of its ITV-1 patented therapeutics for treating HIV leading to the planned clinical trials under the European Medicine Agency (the "EMA"). A commitment for funding of the cost of clinical trials under EMA guidelines and cost associated with the issuance of an EMA permit are part of the negotiated agreements. Under the Mutual Recognition Agreement (the "MRA") between the EMA and the United States Federal Drug Administration (the "FDA"), the Company's belief is that issuance of the EMA permit for the ITV-1 compound should qualify ENZC's treatment for recognition by the FDA. IMBL has entered negotiations to engage Clinic Design to begin the clinical trials that is expected to be required under EMA standards. In addition, the Company is negotiating with an International known and respected European Contract Manufacturing organization ("CMO") to manufacture the required quantities of the ITV-1 Treatment to facilitate the clinical trials and permitting process under EMA guidelines.
https://marketwirenews.com/news-releases/enzolytics-finalizes-documentation-with-internationa-8973953024499637.html
CHARLES has EVERYTHING COVERED
Toxicity and ENZC:
Toxicity or should I say "lack there of" is part of ENZC secret sauce.
The Company has also pioneered a proprietary method for creating human cell lines that produce fully human monoclonal antibodies directed against many infectious diseases. One antibody (designated as CLONE 3) has been demonstrated in tests in 5 international labs to fully neutralize over 95% of all strains and viral subtypes of HIV-1 against which it has been tested.
These HIV therapeutics may be used as an immunotherapeutic treatment for individuals with HIV/AIDS. They may also be developed for use as a prophylactic and therapeutic vaccine to prevent uninfected populations from contracting the HIV virus. Treatment using the fully human anti-HIV antibody will be far superior to current ARV therapy for several significant reasons: (1) the therapy will be effective and non-toxic, (2) will not require lifetime treatment and (3) will be far less expensive.
http://enzolytics.com/our-technology/
Inactivated Pepsin Fragment (IPF) Technology
One Company technology, invented by Harry Zhabilov the CSO of the Company, includes a patented antiviral peptide that has been tested in clinical studies at the National Center of Infectious and Parasitic Diseases in Bulgaria. This therapeutic, known as ITV-1, is a suspension of Inactivated Pepsin Fragment (IPF), a purified extract of porcine pepsin. ITV-1 has been shown to strengthen the immune system and may be used to facilitate a broad range of applications. ITV-1 has been tested in HIV patients in a clinical trial conducted under the strict guidelines of the European Union. HIV patients tested in these trials showed the following beneficial outcomes:
Improvement in the immune indices in the absolute number of Ly, CD3 T, CD4 T, CD8 T, B Ly, NK and in the percentage of CD3 T, CD4 T, CD8 T, B Ly, NK, and of the index CD4/CD8.
Decrease in the viral load.
Demonstrated beneficial effect on opportunistic infections.
Demonstrated very good compatibility with all of the other modern antiretroviral drugs.
Demonstrated very good tolerance in all patients and complete absence of side effects.
This Enzolytics anti-HIV treatment is now being advanced through the certification stage, after which it will be available for patient therapy. ITV-1 also has also demonstrated a positive effect on different kinds of cancer due to its ability to stimulates the immune system.
http://enzolytics.com/our-science/
ITV, produced by Enzolytics, Inc. is a brand-new specific protein for the treatment of HIV and other viral infections. For the
first time a naturally occurring strong binding with gp41 HIV-1 envelop protein “in vitro” was demonstrated.
Current market sales indicate that the majority of products show annual sales of 100 plus million, with a significant number
ranging from 300 million up to 1 billion dollars in annual sales. Many of the major drug companies, have entered into
partnership agreements with newcomers, or with companies in different stages of development in the research pipeline,
combining current ARVs with new drug families that impact the HIV/AIDS virus through different mechanisms of action.
Partnerships of this nature are a direct result of the major seven Pharmas who control a market with a potential of reaching
over $ 15 billion in year 2018, prevent their control and stake in the market share from sliding, due to numerous issues,
among which it is important to note, compliance to the drug regimen, adverse reactions to their chemotherapeutic agents
impacting the human organs, cost, and eventual viral resistance.
In summation our product’s differentiation is based on:
1- Minimal and minor side effects
2- Zero toxicity issues
3- Tremendous cost savings
4- Short and limited treatment cycle
5- Easier Compliance adherence
6- Zero risk of viral resistance and mutation
https://backend.otcmarkets.com/otcapi/company/financial-report/270351/content
How important is TOXICITY?
What is toxicology?
Toxicology is a field of science that helps us understand the harmful effects that chemicals, substances, or situations, can have on people, animals, and the environment. Some refer to toxicology as the “Science of Safety” because as a field it has evolved from a science focused on studying poisons and adverse effects of chemical exposures, to a science devoted to studying safety.
Toxicology uses the power of science to predict what, and how chemicals may cause harm and then shares that information to protect public health. When talking about toxicology it is important to keep a few things in mind.
Not everyone will respond to substances in exactly the same way. Many factors, including the amount and duration of exposure, an individual’s susceptibility to a substance, and a person’s age, all impact whether a person will develop a disease or not. There are times in a person’s life when he or she may be more susceptible to chemicals. These times may include periods of active cell differentiation and growth in the womb and in early childhood, as well as during adolescence, when the brain is continuing to develop. Just because someone is exposed to a harmful substance, does not always mean they will get sick from it.
The dose of the chemical or substance a person is exposed to is another important factor in toxicology. All substances have the potential to be toxic if given to humans and other living organisms in certain conditions and at certain doses or levels. For example, one or two aspirins may be good for you, but taking a bottle of aspirin may be harmful. The field of toxicology tries to understand and identify at what dose and through what exposure a substance poses a hazard.
Toxicologists also realize that even low-dose exposures that may seem insignificant may have biological meaning or lead to an adverse health effect if the exposure is continuous or happens during a critical window of development.
What is a toxicologist?
A toxicologist is a scientist who has a strong understanding of many scientific disciplines, such as biology and chemistry, and typically works with chemicals and other substances to determine if they are toxic or harmful to humans and other living organisms or the environment.
Just like there are different types of doctors, there are different types of toxicology specialists.
A toxicologist working in the pharmaceutical industry, for example, might work to make sure that potential new drugs are safe for testing in clinical trials for humans.
A toxicologist working at the National Toxicology Program (NTP) might be involved in designing and overseeing studies that create a controlled environment that replicates exposures that humans may encounter. NTP toxicologists work to identify hazards from the chemicals or substances they are studying.
https://www.niehs.nih.gov/health/topics/science/toxicology/index.cfm
How does the science of toxicology improve people’s lives?
Toxicology provides critical information and knowledge that can be used by regulatory agencies, decision makers, and others to put programs and policies in place to limit our exposures to these substances, thereby preventing or reducing the likelihood that a disease or other negative health outcome would occur. For example, the state of California used NTP findings to establish the first in the nation drinking water standard for Hexavalent Chromium. This standard will help reduce people’s exposure to this metallic element. Other benefits of toxicology include:
Government agencies have a sound scientific basis for establishing regulations and policies aimed at protecting and preserving human health and the environment.
Companies, such as pharmaceutical and chemical, are able to develop safer products, drugs, and workplaces.
Consumers have access to information that helps them make decisions about their own health and prevent diseases.
PLANO, TX / ACCESSWIRE / December 14, 2020 / Enzolytics, Inc. (OTC PINK:ENZC or the "Company") has engaged SAMM SOLUTIONS, INC. (DBA BTS Research), through a Master Service Agreement ("MSA"), to conduct a toxicity study on the Company's Flagship compound ITV-1. The Company has previously tested the compound in successful Clinical Trials in Bulgaria, but FDA regulations require separate Toxicity tests before an Investigational New Drug process may begin in the United States.
BTS Research ("BTS") has performed numerous studies for small and large biotech companies since 2001. Enzolytics is planning to schedule the toxicity study in the first quarter of 2021. The MSA provides for ongoing services and studies Enzolytics seeks to conduct and that BTS provides.
The toxicity test is a non-issue as we already know the expected results from the 2020 Annual Report and other documented data:
ITV, produced by Enzolytics, Inc. is a brand-new specific protein for the treatment of HIV and other viral infections. For the first time a naturally occurring strong binding with gp41 HIV-1 envelope protein “in vitro” was demonstrated.
Current market sales indicate that the majority of products show annual sales of 100 plus million, with a significant number ranging from 300 million up to 1 billion dollars in annual sales. Many of the major drug companies, have entered into partnership agreements with newcomers, or with companies in different stages of development in the research pipeline, combining current ARVs with new drug families that impact the HIV/AIDS virus through different mechanisms of action. Partnerships of this nature are a direct result of the major seven Pharmas who control a market with a potential of reaching over $ 15 billion in year 2018, prevent their control and stake in the market share from sliding, due to numerous issues, among which it is important to note, compliance to the drug regimen, adverse reactions to their chemotherapeutic agents impacting the human organs, cost, and eventual viral resistance.
In summation our product’s differentiation is based on:
1- Minimal and minor side effects
2- Zero toxicity issues
3- Tremendous cost savings
4- Short and limited treatment cycle
5- Easier Compliance adherence
6- Zero risk of viral resistance and mutation
The only reason the toxicity study is being done is the FDA requires it. Once it is completed ENZC can submit an Investigational New Drug (IND) application.
The IND application must contain information in three broad areas: Animal Pharmacology and Toxicology Studies - Preclinical data to permit an assessment as to whether the product is reasonably safe for initial testing in humans. Also included are any previous experience with the drug in humans (often foreign use).
I expect no press release on the toxicity study however I expect a release when the IND application is submitted.
The stock price will move according to the the results of the company.
Besides the company unlimited potential, the minor results (getting current, new patent, hired PCAOB auditor, toxicity study etc..) management and board of directors has put ENZC on a trajectory of preeminence.
Will ENZC fill the shoes of such an important distinction?
Time will tell.
The company is just in the development stage with some powerful tools in their closet. The have some processes that the MUST go through to get to the final goals of getting products to the marketplace.
ENZC is very fortunate to be at Texas A&M Institute for Preclinical Studies(TIPS)
TIPS provides translational researchers with unique access to expertise in all major medical and scientific disciplines including surgery, biomedical engineering, advanced imaging, pathology, radiography, interventional cardiology, neurology, animal behavior, chemistry, and engineering.
ENZC have shared their plans, goals mission and commitments as well as updates along the way. What they have shared thus far is just a sliver of what is coming down the road.
We are not even 6 months into this journey and the attention the company is getting is unprecedented. They posses some unique technology that may be the answer to help shutting Covid-19 down or at least keeping it in check.
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-continues-impo
The float will be updated in the very near future when the 2020 annual report is released.
The toxicity test is a non-issue as we already know the expected results from the Annual Report and other documented data:
ITV, produced by Enzolytics, Inc. is a brand-new specific protein for the treatment of HIV and other viral infections. For the first time a naturally occurring strong binding with gp41 HIV-1 envelope protein “in vitro” was demonstrated.
Current market sales indicate that the majority of products show annual sales of 100 plus million, with a significant number ranging from 300 million up to 1 billion dollars in annual sales. Many of the major drug companies, have entered into partnership agreements with newcomers, or with companies in different stages of development in the research pipeline, combining current ARVs with new drug families that impact the HIV/AIDS virus through different mechanisms of action. Partnerships of this nature are a direct result of the major seven Pharmas who control a market with a potential of reaching over $ 15 billion in year 2018, prevent their control and stake in the market share from sliding, due to numerous issues, among which it is important to note, compliance to the drug regimen, adverse reactions to their chemotherapeutic agents impacting the human organs, cost, and eventual viral resistance.
In summation our product’s differentiation is based on:
1- Minimal and minor side effects
2- Zero toxicity issues
3- Tremendous cost savings
4- Short and limited treatment cycle
5- Easier Compliance adherence
6- Zero risk of viral resistance and mutation
The only reason the toxicity study is being done is the FDA requires it. Once it is completed ENZC can submit an Investigational New Drug (IND) application.
The IND application must contain information in three broad areas: Animal Pharmacology and Toxicology Studies - Preclinical data to permit an assessment as to whether the product is reasonably safe for initial testing in humans. Also included are any previous experience with the drug in humans (often foreign use).
I expect no press release on the toxicity study however I expect a release when the IND application is submitted.
Spring is in the AIR and I smell the SCENT of a PRESS RELEASE in the not so distant future.
What will it be?
ENZC news will be released when CHARLES who is Charge has something to report to the shareholders. He has done so in the past and will continue to do so in the future. There is a variety of activities presently going on with ENZC that we know about and many that we don’t.
There have been 19 Press Releases since September 2020 which is about 2 per month. Don’t expect 2 press releases per month but do expect press releases to come when Charles has something to report.
Activities awaiting updates of what we know about:
1. NSF and NIH applications Forthcoming
2. Additional Funding Anytime
3. Texas A&M University Institute for Preclinical Studies. Anytime
4. PCAOB Audit April 2021
5. Toxicity Study Anytime
6. Progress on ENZC plans to further develop additional anti-HIV monoclonal antibodies and to now begin the production of fully human monoclonal antibodies targeting the CoronaVirus Anytime
7. Status on the completion of production of monoclonal antibodies against both the HIV virus and the CoronaVirus Anytime
8. Status of testing in combination the Enzolytics ITV-1 peptide in conjunction with our anti-HIV monoclonal antibodies. There is reason to believe that there will be synergistic effect achieved with this combination therapy. Anytime
9. Status on the process of identifying a clinical research organization for the preparation of pre-IND protocols for submission to the FDA. Anytime
10. GMP manufacturer Anytime
11. Status of finalizing the necessary steps for completing the permitting process for our ITV-1 HIV/AIDS therapeutic in Bulgaria.
Anytime
12. Status of received proposals from FDA approved manufacturers to produce the quantities necessary for such certification. Under Review
13. Results of testing of the newly produced monoclonal antibodies. This includes testing of our now being produced recombinant anti-HIV monoclonal antibodies created from the parent antibody. Such testing is now scheduled for early 2021 at the University of Strasbourg in Strasbourg, France. Additional testing of the Company's antibodies is also being planned at San Raffaele Scientific Institute, Milan, Italy.
Early 2021
14. Acquisition Anytime
15. Status of collaborative opportunities with other drug development companies to expand our product reach. Forthcoming
16. Gilead Relationship to ENZC
17. Eli Lily Relationship toENZC
18. Immunome Relationship to ENZC
There will be other updates of activities we don’t know about however based on the processes of Biotechnologies companies one can surmise what these could possibly be. Anytime
Remember two things.
First and foremost CHARLES is in Charge
Second and very important from the Press Release dated October 19, 2020:
All of our steps are taken with two objectives in mind. First our focus is on creating successful therapeutics against infectious diseases, including HIV and now our focus on the Coronavirus. Secondly, our efforts are also intended to increase the value of our technology and the value of our company - which directly translates into value for our investors. Please know that these are our two guiding objectives with every effort we make.
The link below has all ENZC Press Releases:
https://marketwirenews.com/stock/enzc/news/
ENZC has so much going on that it is hard to grasp. They have in their arsenal the future of medical care in the way of therapeutic platforms first for HIV and Coronavirus and then for 14+ more viruses.
The future of health
How innovation will blur traditional health care boundaries
The life sciences and health care industry is on the brink of large-scale disruption. In a future of health that’s defined by radically interoperable data, open yet secure platforms, and consumer-driven care, what role will you play?
In our vision of the future of health, we view radically interoperable data, artificial intelligence (AI), and open, secure platforms as central to the promise of more consumer-focused, prevention-oriented care. AI will enable major scientific breakthroughs, accelerating the creation of new therapies and vaccines to fight diseases. AI-enabled digital therapeutics and personalized recommendations will empower consumers to prevent health issues from developing. AI-generated insights will influence diagnosis and treatment choices, leading to safer and more effective treatments. Additionally, intelligent manufacturing and supply chain solutions will ensure the right treatments and interventions are delivered at the exact moment needed by the patient. https://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/future-of-health.html?id=us:2ps:3gl:fohc4:awa:lshc:121420:ad3:kwd-472491030708:the%20%2Bfuture%20of%20%2Bmedicine&gclid=CjwKCAiAsaOBBhA4EiwAo0_AnCsF0fPTERNdE4xTI2mbc961uiNTuuR1QoDHglNSC8VOJwNsgqwMIBoC5SoQAvD_BwE
Monoclonal Antibody Techniques
Monoclonal antibodies (mAbs) are monovalent antibodies which bind to the same epitope and are produced from a single B-lymphocyte clone. Monoclonal antibodies are important tools used in biomedical research, in diagnosis of diseases, and in treatment of such diseases as infections and cancer.
What is the value of monoclonal antibody technology?
Monoclonal antibody technology allows us to produce identical antibody molecules in large scale or industrial yields. It should be noted that the emergence of monoclonal antibody technology makes it possible for a variety of applicationsof monoclonal antibodies.
Single B cell antibody technologies
This approach to produce monoclonal antibodies from single human B cells is based on the analysis of the immunoglobulin gene repertoire and reactivity at the single-cell level by the application of reverse transcription-polymerase chain reaction (RT-PCR) and expression vector cloning.
By recognition of selected cell surface markers, individual mouse or human B cells are isolated (e.g., by fluorescence-activated cell sorting), and genes coding for VL and VH fragments are separately amplified by RT-PCR and combined by PCR. For the final production of human mAbs in vitro, H and L chain gene transcripts from each cell are amplified by RT-PCR before cloning and expression in a mammalian system. This method has the virtue of being able to produce many specific human mAbs in a short period. View more about "Single B cell antibody technologies".
https://www.sinobiological.com/resource/antibody-technical/monoclonal-antibody-technology
PLANO, TX / ACCESSWIRE / November 13, 2020 / Enzolytics Inc. (OTC PINK:ENZC) or the "Company" today shared the following update provided by ENZC's Merger target BioClonetics Immunotherapeutics, Inc. ("BCLS" or "BioClonetics"), resulting from the application of proceeds from the initial funding received on October 26, 2020. The full text of the update is presented below.
https://www.otcmarkets.com/stock/ENZC/news/Enzolytics-Inc-Shares-Current-BioClonetics-Immunotherapeutics-Inc-Update?id=280113
The procedure for producing monoclonal antibodies is also significant and our procedure differs from those used by other pharma companies. In some cases, other pharma companies produce "humanized" rat and mouse monoclonal antibodies where the original antibody affinity and specificity are not maintained, and the chances of immunogenicity are increased. Our methodology also differs significantly from other pharma approaches using the transgenic mouse model a human immune system which has been "grafted" within a mouse model] having been "vaccinated" with specific and selected purified CoronaVirus Proteins.
In contrast, our model starts with human "immune-B cells", obtained from convalescent individuals who have recovered from the CoronaVirus. The primary distinction of our process for creating fully human monoclonals is the starting point - namely from human "immune-B cells" from humans who have survived successfully from a "natural" CoronaVirus infection. From these, we then produce antibodies that target conserved immutable sites on the virus - to avoid "virus escape".
Additionally, our antibodies retain the original natural antibody affinity and specificity and have lower risk of immunogenicity when used as a therapeutic. They will provide broad-spectrum coverage against viral variants with increased potency, stability as a single-domain molecule, and, in the recombinant form, will have accessibility to the virus epitopes (binding sites) not accessible with a whole antibody.
PLANO, TX / ACCESSWIRE / December 14, 2020 / Enzolytics, Inc. (OTC:ENZC, Company", )) has engaged SAMM SOLUTIONS, INC. (DBA BTS Research), through a Master Service Agreement ("MSA"), to conduct a toxicity study on the Company's Flagship compound ITV-1. The Company has previously tested the compound in successful Clinical Trials in Bulgaria, but FDA regulations require separate Toxicity tests before an Investigational New Drug process may begin in the United States. https://marketwirenews.com/news-releases/enzolytics-inc-engages-bts-research-to-conduct-toxic-6758170663840334.html
The toxicity test is a non-issue as we already know the expected results from the Annual Report and other documented data:
ITV, produced by Enzolytics, Inc. is a brand-new specific protein for the treatment of HIV and other viral infections. For the first time a naturally occurring strong binding with gp41 HIV-1 envelope protein “in vitro” was demonstrated.
Current market sales indicate that the majority of products show annual sales of 100 plus million, with a significant number ranging from 300 million up to 1 billion dollars in annual sales. Many of the major drug companies, have entered into partnership agreements with newcomers, or with companies in different stages of development in the research pipeline, combining current ARVs with new drug families that impact the HIV/AIDS virus through different mechanisms of action. Partnerships of this nature are a direct result of the major seven Pharmas who control a market with a potential of reaching over $ 15 billion in year 2018, prevent their control and stake in the market share from sliding, due to numerous issues, among which it is important to note, compliance to the drug regimen, adverse reactions to their chemotherapeutic agents impacting the human organs, cost, and eventual viral resistance.
In summation our product’s differentiation is based on:
1- Minimal and minor side effects
2- Zero toxicity issues
3- Tremendous cost savings
4- Short and limited treatment cycle
5- Easier Compliance adherence
6- Zero risk of viral resistance and mutation
The only reason the toxicity study is being done is the FDA requires it. Once it is completed ENZC can submit an Investigational New Drug (IND) application.
The IND application must contain information in three broad areas: Animal Pharmacology and Toxicology Studies - Preclinical data to permit an assessment as to whether the product is reasonably safe for initial testing in humans. Also included are any previous experience with the drug in humans (often foreign use).
I expect no press release on the toxicity study however I expect a release when the IND application is submitted.
Also I don’t expect a press release on the website because once it is up and running there is no reason to tell us as we will already know.
https://twitter.com/SportsCardsTVMe/status/1361002549608931328
https://twitter.com/drgauravchandra/status/1361006189249757187?s=19
COLLEGE STATION, TX / ACCESSWIRE / February 1, 2021 / Enzolytics, Inc. (OTC PINK:ENZC)(the "Company") today announced it has identified seven additional conserved, expectedly immutable sites on the HIV virus against which it plans to produce targeted anti-HIV monoclonal antibodies. The Company's primary anti-HIV monoclonal antibody targets one conserved site on the HIV virus, which site is 98% conserved (either directly or by way of conservative amino acid substitutions) over all 87,336 HIV isolates which have now been curated (analyzed) by the Company using Artificial Intelligence (AI). Additional conserved target sites (some with 98% conserved sequences) have now been identified against which fully human anti-HIV monoclonal antibodies will be produced in its lab on the campus of Texas A&M University in the University's Institute for Preclinical Studies. The significance of producing multiple monoclonal antibodies targeting multiple conserved sites is recognized by experts as a critical approach to effective therapy. This allows the administration of a "cocktail" of antibodies, all targeting conserved and expectedly immutable sites.
The Company is also applying Artificial Intelligence [AI] to scan the hundreds of thousands of isolates that exist in 14 other prevalent viruses, ranging from influenza to Rabies to Ebola. Using the Company's proprietary technique for producing fully human monoclonal antibodies directed against these infectious diseases, the Company will produce multiple neutralizing monoclonal antibodies against these viruses. The significance of this approach is well recognized by experts in virology due to the ability of all viruses to mutate and render ineffective initially developed therapeutics.
Production of the Company's primary anti-HIV monoclonal antibodies is underway at Genscript Labs. Testing of these newly produced monoclonal antibodies is scheduled for early 2021 at the University of Strasbourg in Strasbourg France. Thereafter, Macaque trials are planned at the California National Primate Research Center, Univ. of California, Davis, CA.
Additional information on the progress and Company facilities will be part of the new Company website expected to be rolled out in the coming days.
Quote:
CEO Charles Cotropia stated, "The Company is making significant progress on both of its therapeutic platforms: first, on the identification of prime target sites on both the CoronaVirus and the HIV virus and the creation of neutralizing antibodies directed against these sites, and second, on advancing its ITV-1 peptide therapeutic for patient application in the EU."
Quote:
CSO Harry Zhabilov stated, "With the Bulgarian Drug Administration joining the European Medicine Agency and being recognized under the Mutual Recognition Agreement with the FDA, once we have successfully finished the permitting process the Company will be able to pursue FDA approval for ITV-1. We are currently investigating the required steps but feel confident that this is a viable option for the ITV-1 patented therapy."
https://marketwirenews.com/news-releases/enzolytics-announces-the-discovery-of-seven-newly-id-7491922242125190.html
ENZC have accomplished many milestones to get their products to the marketplace. We come a long way in a short period of time however much more work is necessary and unforeseen circumstances to overcome such as the situation in Bulgaria. Getting our first product to the marketplace is a priority as it is needed and will be done as soon as possible. Whether that is weeks or months away is not only up to the company but also any requirements set forth by regulatory agencies as we have seen with the toxicity test. ENZC is fortunate to be at the The Texas A&M Institute for Preclinical Studies (TIPS)
Quote:
TIPS provides translational researchers with unique access to expertise in all major medical and scientific disciplines including surgery, biomedical engineering, advanced imaging, pathology, radiography, interventional cardiology, neurology, animal behavior, chemistry and engineering. This direct association with the College of Veterinary Medicine and Biomedical Sciences gives researchers the ability to pursue knowledge in a top research university, where cutting-edge technology and scientists at the head of their field can be accessed.
ENZC priority for obvious reasons is the monoclonal antibodies for HIV and CoronaVirus.
FDA is considering all possibilities by any means that can shut Covid-19 down or keep it in check. ENZC technology can certainly help in this process. It is only a matter of time when we find out just how involved we are either leading the charge or part of a collaboration with another company.
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-continues-important-work-support-medical-product-development-address
For therapeutics, particularly virus-targeting monoclonal antibodies, we are considering approaches to help expedite drug development in this key area, including discussing appropriate regulatory flexibilities. We are aware that some of the neutralizing monoclonal antibodies that have been authorized or are under development are less effective against some of the COVID-19 variants that have emerged, and we are working with drug developers to accelerate the evaluation of new antibodies that could be effective against mutations. Relying on our growing experience with this class of drugs, our teams are discussing approaches to the generation and evaluation of pre-clinical, clinical and chemistry, manufacturing and controls data.
They are already working on 14 more prevalent viruses that they will eventually produce monoclonal antibodies to combat them.
The work ENZC is accomplishing is neither easy or quick however with the previous research and trials that have already taken place along with the laboratory at TIPS will certainly help in the process. There may be long stretches without press releases as the company works through the necessary processes to get their products to the marketplace. Patience is key and as long as Charles and team members take care of business everything else will fall into place as we have seen thus far.
Charles will release news when he has something to share.
Always have and Always will!
Remember two things.
First and foremost CHARLES is in Charge
Second and very important from the Press Release dated October 19, 2020:
All of our steps are taken with two objectives in mind. First our focus is on creating successful therapeutics against infectious diseases, including HIV and now our focus on the Coronavirus. Secondly, our efforts are also intended to increase the value of our technology and the value of our company - which directly translates into value for our investors. Please know that these are our two guiding objectives with every effort we make.
The link below has all ENZC Press Releases:
https://marketwirenews.com/stock/enzc/news/
Valued at $23million 4 months ago, now pushing $1billion
Who That?
Enzc
ENzc
ENZc
ENZC
There is no LIMIT for ENZC stock price appreciation!!!
Too much going on with ENZC.
The company could drop press release any time that WILL send the stock past all previous HIGHS!
FACTS we KNOW:
1. AI
2. Monoclonal Antibodies being produced
3. Toxicity study results imminent
4. 19+ Patents
5. 2020 Annual Report imminent
6. PCOAB for 2019 and 2020 expected next month
7. The application for OTCQB is being prepared for submission upon issuance of the Audited Statements
8. Charles is in Charge
What we don't know:
1. Relationship to Gileads?
2. Relationship to Eli Lily?
3. Relationship to Immunome?
4. Acquisition?
ENZC has used AI to advance/expedite the production of Monoclonal Antibodies.
ENZC is still at the ground floor with the foundation set, the cornerstone in place and is building a solid company that will rival, challenge and change the landscape of the pharmaceutical world in a way that has never be seen before.
Enzolytics continues its onward and upward march towards strategic partnerships and a stronger Intellectual Property portfolio.
#ENZC #HIV #COVID19 #AI #Gileads #EliLilly #Patent #Monoclonal #Antibodies #acquisition #partnership #immunome
The Company is actively progressing to produce monoclonal antibodies against many other viruses. The proprietary methodically used by the Company will be employed to produce monoclonal antibodies against numerous other virus and using "AI", the Company is curating the know sequences of the following viruses and intends to both seek patent coverage and produce monoclonal antibodies targeting conserved sequences These viruses include:
HIV-2, Influenza A and B, H1N1 influenza, Respiratory syncytial virus (RSV), Small-Pox, Ebola Virus, Tetanus, Diphtheria, HTLV-1/2, Rabies, Herpes zoster, Varicella zoster, Anthrax, Mason-Pfizer monkey virus (MPMV) and Visna virus (VISNA). Patent applications will be filed claiming the inventive findings. Patent claims will cover the discovered epitope/antigens, with proposed vaccine claims, antibody claims, and related prophylactic/therapeutic method claims relating to these identified epitope/antigens.
ENZC cred·i·bil·i·ty
the quality of being trusted and believed in.
We at ENZC follow the SCIENCE and SCIENCE leads to results!
Why with so many "other companies" introducing monoclonal antibodies is ENZC needed?
CEOCFO: What are you looking at regarding COVID?
Mr. Cotropia: We have produced an HIV monoclonal antibody that had been successfully tested in five international labs where it neutralized 95% of all strains against which it was tested. There are 6000 different strains of the HIV virus now known. We know that that our antibody is effective and we know the target site on the virus resulting in neutralization of the HIV virus. For an antibody to be effective it has to attack a neutralizable site on the virus that is always there, does not mutate from strain to strain. Knowing the binding site of our HIV monoclonal antibody, and then examining the CoronaVirus amino acid sequence, a correlation in the structures has been identified by our CSO, Dr. Joseph Cotropia, between the CoronaVirus and the HIV virus. With knowledge of these homologous viral structures, monoclonal antibodies will be created that target the corresponding “Achilles Heel” site on the CoronaVirus, an expected conserved immutable and neutralizable site on the virus. Additionally, using artificial intelligence, we will examine the numerous different strains of the virus to identify other conserved sites and produce additional monoclonal antibody targeting them. This is for the purpose of producing a “collection” or “cocktail” of antibodies for therapeutic use. We recognize that there are now known over 16,000 different variations or strains of the CoronaVirus, each slightly different due to mutation. A successful monoclonal antibody “cocktail” therapy must include multiple antibodies that specifically target several immutable sites and which results in neutralization.
For example, we all now know that President Trump received a combination of two Regeneron antibodies. Eli Lilly has also produced an anti-CoronaVirus antibody. However, what we do not know is whether those antibodies will be successful as the virus mutates. As I mentioned, there are now known 16,000 different variants to the CoronaVirus and immutable sites must be the targeted in order to be effective in the long run.
Also, as all experts in the field of monoclonal antibodies agree, including Dr. Anthony Fauci, head of the NIAID/NIH, to have an effective therapy, we must have multiple monoclonal antibodies that target various sites on the virus - and in fact, even President Trump was given a cocktail of two. Therefore, it is imperative to identify conserved neutralizing binding sites on the CoronaVirus, and create multiple monoclonal antibodies that target these critical neutralizable and immutable structures. It is like finding a needle in a haystack and retrieving the needle; you must identify the immutable sites on the virus and then create and characterize fully human monoclonal antibodies that target those sites. The process described here will be our focus and for the reason that success has already been achieved with regard to the production of broadly neutralizing antibodies directed against the HIV virus, we expect success will likewise be achieved in production of broadly neutralizing human monoclonal antibodies directed against the CoronaVirus.
Here is why we are confident in our technology.
It will be imperative that produced antibodies target a conserved and immutable site on the virus - otherwise the antibody (over time) will be rendered ineffective due to mutation - known as “virus escape”. Our anti-HIV monoclonal antibody targets an immutable virus site on the HIV virus - one that is constant within virtually all 6000 now known different HIV isolates (strains) of the virus. The CoronaVirus has structure correlative to that of the HIV virus. Because our primary anti-HIV monoclonal antibody has been proven to neutralize numerous different strains of the HIV virus in tests in 5 international labs, and knowing the binding site on the HIV virus to which our antibody binds resulting in neutralization, this knowledge provides insight necessary to identifying corresponding structure (amino acid sequences) on the CoronaVirus that should be targeted to effectively neutralize the CoronaVirus. Moreover, we have proprietary methodology needed to produce anti-CoronaVirus monoclonal antibodies targeting such known - to us - sites.
Whether it is ENZC or any other stock, what will matter when the dust settles is the results produced by the company. In ENZC case, results have been positive with somme setbacks. ENZC has made adjustments to the setbacks and continues to move forward.
It is a DOG FIGHT!!!
ENZC is PEROULATING for the BREAKOUT!!!
ITV-1
Enzolytics is a Texas based biotechnology company with both patented anti-HIV therapeutics and a proprietary methodology for producing fully human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The Company has clinically tested its anti-HIV therapeutics known as ITV-1. ITV-1 is a suspension of Inactivated Pepsin Fragment (IPF), a purified extract of porcine pepsin. ITV-1 has been shown to strengthen the immune system and may be used to facilitate a broad range of applications. ITV-1 has been tested in HIV patients in a clinical trial conducted under the strict guidelines of the European Union where it demonstrated beneficial outcomes. Additionally, the Company has created a proprietary cell line that produces fully human monoclonal antibodies that target and neutralize the HIV virus.
The Company has also pioneered a proprietary method for creating human cell lines that produce fully human monoclonal antibodies directed against many infectious diseases. One antibody (designated as CLONE 3) has been demonstrated in tests in 5 international labs to fully neutralize over 95% of all strains and viral subtypes of HIV-1 against which it has been tested.
ITV-1 has been through Phase I, II and III clinical Trials however due to ENZC being informed that the inclusion of the BDA in the EMA restricted the permitting of our Treatment by the BDA and the permitting will now be done by the EMA for all the European Union. As a result, some, if not all of the Phase III clinical trials may need to be completed under the EMA standards.
Volume is among the most basic and effective concepts to understand when trading stocks. Volume is actually the number of shares (or contracts) that trade over a certain period of time (e.g.a day for daily timeframe). The higher the volume, more active the shares. Volume plays a significant role in the buying and selling of the stocks. Most traders combine the volume with the price of the stock to take the trading decision.
The most significant rule is this: volume precedes price. Generally, before a stock price moves, the volume comes into play. This is explained in detail in the next section.
Increasing price along with increasing volume, confirms the uptrend and is a healthy sign of a strong uptrend and hence is Bullish.
Decreasing price along with decreasing volume is Bullish because it indicates weak retail investors are selling and hence is not a reason to worry. This is probably a good thing because once the consolidation happens, the breakouts will be much stronger.
Decreasing price along with increasing volume indicates that the big guys are selling and hence is Bearish.
Increasing price along with decreasing volume indicates weak retail investors are buying and is a cautionary sign and should make you doubt the upward price movement (i.e. it is Bearish).
But it is not always possible to have exact bullish/bearish pattern as shown in above figures. In fact, what is important is that the price movement should happen on high volume, and this can be done by ensuring that the volume is above the 50-day moving average. Any sign that volume is above the 50-day SMA indicates accumulation and vice versa below the 50-day SMA indicates distribution.
Volume and Breakouts
Volume can help to verify all sorts of breakouts. A stock is said to break out on strong volume, when a strong resistance is broken on high volume. A breakout taking place on rising volume is a valid breakout, while a breakout with low volume is more likely to be false.
When a stock breaks out of a strong resistance on high volume, it is a great entry point and if used properly can help in identifying multi-baggers. One of the important factors to look for in such a stock are the bullish price and volume patterns, before the breakout and at the time of the breakout.
Stock Volume and Price Divergence
Divergence occurs when price movement is not confirmed by the indicator. There are two kinds of Indicator Divergence: Negative Divergence and Positive Divergence. In many cases, these divergences can indicate a potential reversal.
Declining volume in the course of an uptrend illustrates that interest is decreasing. Price can still continue to rise on declining volume, though. Declining volume foreshadows an eventual reversal, but shouldn’t be acted upon until the price actually breaks the uptrend.
Declining volume during a downtrend doesn’t tell us a lot because a lack of interest can either indicate a lack of buying interest, which continues to push the price lower, or a lack of selling interest, which could eventually push the price higher.
Volume and Price Reversals
Volume spikes are often the result of news driven events, it indicates that buyers or sellers may be exhausted. At the point when the volume spike happens after a run brings down in price, it demonstrates sellers could soon be depleted, and without any sellers left to push the price down, the price will rise. At the point when the volume spike happens after a run higher in price, it demonstrates buyers could soon be depleted, and without any buyers left to push the price up, the price will drop. This volume spike will often prompt to distinctive reversals since the moves are unsustainable due to the imbalance of supply and demand.
Blow-Off Tops and Bottoms
Blow-Off Tops and Bottoms are usually contrary to the price volume patterns indicated above . e.g. a Blow-Off top is a chart pattern that indicates a steep and rapid increase in a stock’s price on high trading volume followed by a steep and rapid drop in price and volume is referred to as a Blow-Off Top.
Blow-Off Tops are usually formed at the tail end of long-term uptrends and are a sign that the overall market is peaking. They are caused by the sudden rush of small investors to get into the stock. In fact towards the end of long-term uptrends, a lot of the stocks will exhibit such behavior, so if you notice such behavior in many stocks, that is a sign that the overall bull market is about to end. E.g., in Jan 2008, when the SENSEX peaked at 21000, a lot of stocks exhibited this pattern.
Similarly, Blow-Off Bottoms usually happen at the tail end of long-term bear markets and usually indicate that the bear market is going to end. A Blow-Off Bottom is caused by panic selling causing the stock to go down in a steep downtrend on very high volume, after which the stock starts going up.
The Bottom Line
A volume is a significant tool because it shows the conviction of buyers and sellers. Volume should never be used independently of price action to determine to buy or to sell patterns, but it is an invaluable tool to gain insight into the markets and determine the current price trend.
Volume Price Trend Indicator (VPT)
What Is a Volume Price Trend Indicator (VPT)?
The volume price trend (VPT) indicator helps determine a security’s price direction and strength of price change. The indicator consists of a cumulative volume line that adds or subtracts a multiple of the percentage change in a share price’s trend and current volume, depending upon the security’s upward or downward movements.
Understanding the Volume Price Trend Indicator (VPT)
The volume price trend indicator is used to determine the balance between a security’s demand and supply. The percentage change in the share price trend shows the relative supply or demand of a particular security, while volume indicates the force behind the trend. The VPT indicator is similar to the on-balance volume (OBV) indicator in that it measures cumulative volume and provides traders with information about a security’s money flow. Most charting software packages have the VPT indicator included.
Trading With the Volume Price Trend Indicator
Signal Line Crossovers: A signal line, which is just a moving average of the indicator, can be applied and used to generate trading signals. For example, a trader may buy a stock when the VPT line crosses above its signal line and sell when the VPT line passes below its signal line.
Confirmations: The VPT indicator can be used in conjunction with moving averages and the average directional index (ADX) to confirm trending markets. For instance, a trader could buy a stock if the 20-day moving average is above the 50-day moving average and accompanied by rising VPT indicator values. Conversely, the trader may decide to sell if the 20-day moving average is below the 50-day moving average and the indicator’s values are falling.
The ADX also measures trend and momentum and can be used with the VPT indicator to confirm that a market is trending. ADX readings above 25 indicate that a security is trending, while readings below 25 indicate sideways price action. Therefore, a trader could buy when the ADX is above 25 and the VPT line is above its signal line. They could sell when the ADX has a value below 25 and the VPT line is below its signal line.
Divergence: Traders can use the VPT indicator to spot technical divergence. Divergence occurs when the indicator makes a higher high or a lower low, but the security’s price makes a lower high or a higher low. Traders should place a stop-loss order above the most recent swing high or below the most recent swing low to minimize risk.
I have know idea however even if they were how manyy could they buy on the cheap?
Eventhough there are 1,670,830,512 shares in the float I don't blieve there are a lot available for sale especially at this level.
The UNKNOWNS are too numerous to mention in one post however here are a few of the BIGGIES:
When wiil BIG Pharma JUMP in?
When will the PCOAB audit be completed?
Where is the company at in getting Clone 3 Pre-clinical primate macaque trials to validate effectiveness in primates.
Has ENZC produced the recombinant of the Clone 3 antibody for testing and later patient therapy.
Who is the major pharmaceutical company that has indicated that it will promote our technology upon our successful completion of the next step of producing and testing what is known as the “recombinant” form of Clone 3.
ENZC Technology
ITV-1
Enzolytics is a Texas based biotechnology company with both patented anti-HIV therapeutics and a proprietary methodology for producing fully human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The Company has clinically tested its anti-HIV therapeutics known as ITV-1. ITV-1 is a suspension of Inactivated Pepsin Fragment (IPF), a purified extract of porcine pepsin. ITV-1 has been shown to strengthen the immune system and may be used to facilitate a broad range of applications. ITV-1 has been tested in HIV patients in a clinical trial conducted under the strict guidelines of the European Union where it demonstrated beneficial outcomes. Additionally, the Company has created a proprietary cell line that produces fully human monoclonal antibodies that target and neutralize the HIV virus.
The Company has also pioneered a proprietary method for creating human cell lines that produce fully human monoclonal antibodies directed against many infectious diseases. One antibody (designated as CLONE 3) has been demonstrated in tests in 5 international labs to fully neutralize over 95% of all strains and viral subtypes of HIV-1 against which it has been tested.
ITV-1 has been through Phase I, II and III clinical Trials however due to ENZC being informed that the inclusion of the BDA in the EMA restricted the permitting of our Treatment by the BDA and the permitting will now be done by the EMA for all the European Union. As a result, some, if not all of the Phase III clinical trials may need to be completed under the EMA standards.
Clone 3
Clone 3 is what’s known as a monoclonal antibody—a laboratory-made molecule produced by repeated replication of a single parent cell.
Monoclonal antibodies mimic the ones your body naturally produces as part of your immune system's response to germs, viruses and other invaders. Because monoclonal antibodies come from a single cell source, they’re engineered to target a specific part of a virus. The Clone 3 monoclonal antibodies that we’re developing target a specific site on HIV and as a result neutralizes the virus.
These HIV therapeutics may be used as an immunotherapeutic treatment for individuals with HIV/AIDS. They may also be developed for use as a prophylactic and therapeutic vaccine to prevent uninfected populations from contracting the HIV virus. Treatment using the fully human anti-HIV antibody will be far superior to current ARV therapy for several significant reasons: (1) the therapy will be effective and non-toxic, (2) will not require lifetime treatment and (3) will be far less expensive.
Thus, for the patient, immunotherapy will be remarkably different — it will be safer, provide a much-needed immunotherapeutic cure rather than requiring lifelong treatment and costs substantially less than current antiretroviral therapy.
The Company also has created human cell lines that produce human antibodies against other infectious diseases, including rabies, influenza, tetanus and diphtheria. As a part of its mission, the Company is testing these antibodies to prepare them for use as therapies against these diseases.
Final testing of the Company’s anti-HIV mAb in PBMC neutralization assays is currently being completed, to be followed by animal trials at the California National Primate Research Center, UC Davis (Davis, CA).
The anti-HIV therapies of Enzolytics’ two technologies, that produced by Enzolytics and created at BioClonetics, are expected to be synergistic in treating HIV. Tests to establish such synergy are scheduled.
Anti-CoronaVirus Monoclonal Antibodies
The Company’s proprietary methodology may also be applied to produce monoclonal antibodies against other infectious diseases. This includes production of monoclonal antibodies against the SARS-CoV-2 virus (CoronaVirus), as well as other infectious diseases including HIV-2, anthrax, smallpox, H1N1 influenza, herpes zoster, varicella zoster, Rh (+) auto-immune disease and the Ebolavirus. A Company program is underway to produce monoclonal antibodies against the SARS-CoV-2 virus (CoronaVirus). Such production will be achieved using the proprietary methodology used to previously produce monoclonal antibodies (mAbs) against HIV, rabies, influenza A, influenza B, tetanus and diphtheria.
Having produced neutralizing antibodies against the HIV-1 virus and recognizing a significant correlative structure between the HIV virus and the SARS-CoV-2 virus, the Company is developing anti-SARS-Cov-2 (CoronaVirus) monoclonal antibodies using its proprietary technology. These antibodies are expected to provide a therapeutic for patients infected with COVID-19. Identification of these neutralizable epitopes also will permit the production of a phage display anti-SARS-CoV-2 (CoronaVirus) vaccine.
Production of these monoclonal antibodies is being conducted in the Company’s lab at the Texas A&M University Institute for Preclinical Studies in College Station, Texas.
So we are trading at one half of what we were trading at just one month ago.
Why?
The stock ran along with the rest of the OTC and then made a correction and has settle $0.30 cent range while even hitting a TEMPORARY low of $0.22 cents along the way.
ENZC will trade in this RANGE until the stock MOVES UP on its next leg.
WELCOME TO OTC LAND OF THE PUMP AND DUMP SHARE SELLING SCAMS GOING WILD EVERY DAY EXCEPT for ENZC
IF THIS ENZC EVER BREAKS .22, IT WILL BE THE BEGINNING of A MASSIVE and I MEAN MASSIVE REVERSAL.
IT'S NOT TOO LATE TO GET IN ON THIS STATE of the ART ZIP CODE CHANGER.
THe LOWER ENZC stock price DROPS the HIGHER the RISE on the next leg up.
It is about ot get BUSY up here up in here.
BULLS versus bears EPIC fight!!!
It appears the BEARS are holding on to a slim lead in the scoring however the BULLS have an awesome CHOKE HOLD on the bears that shold lead to a VICTORY!!!
Stay Tuned for the FINAL RESULT
ENZC is ready for a Big Move - 250% Gains Predicted?
ENZC could be ready to Beat the Street! Get our Full Analyst Report 100% Free before you Trade. Benefits: Real-Time Notifications, Complete Stock Trading Report, E-Mail And SMS Text Messaging, Ongoing Educational News.
https://beatpennystocks.com/stock-report/?symbol=ENZC&gclid=CjwKCAjwxuuCBhATEiwAIIIz0TRZza-2sKotqCfr5V9SROKiH0zJkyvOKi8hHmhUnSQFrRZoYQuflhoCWNkQAvD_BwE
You said:
You said:
You said:
THe LOWER ENZC stock price DROPS the HIGHER the RISE on the next leg up.
It is about ot get BUSY up here up in here.
BULLS versus bears EPIC fight!!!
It appears the BEARS are holding on to a slim lead in the scoring however the BULLS have an awesome CHOKE HOLD on the bears that shold lead to a VICTORY!!!
Stay Tuned for the FINAL RESULTS!
The EPIC RISE of ENZC has not even begun YET!
Fron trips to the 90s and has been LINGERING around the 30s for weeks!!!
What wll the next LEG UP deliver?
DOLLARS!!!!
CENTS!!!
TENS of DOLLARS!!!
NOBODY KNOWS however you have to be in to WIN.
ENZC will have its day in court or should I say its day at the TRACK so it can RUN RUN RUN!!!
Some of the Most Successful BIOTECHS Penny Stocks RUNS in History
Will ENZC RUN challange these companies runs?
Don't Know however I will be here to find out.
Axsome Therapeutics Inc. (NASDAQ: AXSM)
Axsome Therapeutics Inc. is a U.S.-based therapeutics company that gained 3,812% throughout 2019 and into 2020.
We can link its 2019 success to its trial of a new drug. In this case, it was AXS-05, a treatment for major depressive disorders.
But, that’s not all…
In late 2019, the FDA also awarded a breakthrough Therapy Designation to AXS-05.
AXSM started January 2019 trading for less than $10 per share. By January 2020, AXSM hit highs of over $100 per share. And in October 2020, it traded around $70 per share.
Provention Bio Inc. (NASDAQ: PRVB)
In the biotech sector, Provention Bio is a ‘penny stock poster child.’
PRVB had big news with its Phase 3 drug trial that could potentially delay or even prevent type 1 diabetes.
This stock has more than tripled from November 2018. And yet there still seem to be market murmurs that it’s underestimated.
We’ve all heard that before…
PRVB started January 2019 trading at $2.55 , and by December 2019, it was trading at $14.97.
By July 2020, PVRB hit a new all-time high trading at $17 per share.
Mylan N.V. (NASDAQ: MYL)
MYL is a pharmaceutical company worth over $8 billion today. The lows on the chart below are just under $6 per share, not technically a penny stock.
But this move is impressive. Runs from $6 to over $70 per share don’t happen often. I’d still consider this an example of a successful penny stock.
Novavax Inc. (NASDAQ: NVAX)
I saved one of the most successful penny stocks for last. NVAX had a huge run this year.
This pharma play ripped from $3.54 at its low to over $331 per share at its highs — all in under a year, thanks to the crazy volatility of the coronavirus market.
Sound Management
In real estate, it’s all about “location, location, location." For penny stocks, it’s about “management, management, management." Sound management can turn around a struggling firm and launch a startup to new heights. More importantly, experienced and ethical management that have a vested interest in the company via share ownership can provide investors with a sense of security.
Of course, superstar managers aren't often found working for penny stock companies, but there are a few examples. Take Concur Technologies, which bounced back from its post-tech bubble price of $0.31 and got bought out in 2014 at $129 per share. This remarkable comeback is owed to many factors, but one that stood out was the strong vested interest of President and COO Rajeev Singh. Singh, who had co-founded the company in 1993, filled a plethora of management roles over the firm’s lifespan before he finally stepped down after Concur’s acquisition by software giant SAP SE (SAP).
The Bottom Line
Penny stocks are extremely volatile and speculative by nature. As most trade on OTC exchanges or via pink sheets, where listing standards are lax, penny stocks are susceptible to manipulation and fraud. Still, the potential to make large returns is a strong allure, driving risk-taking investors into taking positions in these securities. Though many penny stocks go bust, if an investor exercises careful fundamental analysis and picks sound management teams, they could find the coveted diamond in the rough.
Makes you wonder WHY ENZC is getting so MUCH ATTENTION from all over the place.
http://denverscientificai.net/
https://aumag.org/2013/09/26/the-future-of-clone-3/
https://www.cameo.com/v/6050d64aaa8f03001dbd6a01
https://www.cameo.com/v/6050e110e4e283001d59bd9f
ENZC is ready for a Big Move - 250% Gains Predicted?
ENZC could be ready to Beat the Street! Get our Full Analyst Report 100% Free before you Trade. Benefits: Real-Time Notifications, Complete Stock Trading Report, E-Mail And SMS Text Messaging, Ongoing Educational News.
https://beatpennystocks.com/stock-report/?symbol=ENZC&gclid=CjwKCAjwxuuCBhATEiwAIIIz0TRZza-2sKotqCfr5V9SROKiH0zJkyvOKi8hHmhUnSQFrRZoYQuflhoCWNkQAvD_BwE
The Company continues audits of the Company's current and prior year Financial Statements. An application for OTCQB is being prepared for submission upon issuance of the Audited Statements. The Company plans to complete the two-year audit as quickly as possible but will file the December 31, 2020 Annual Report Financial Statements pursuant to the OTC Markets Pink Basic Disclosure Guidelines. The Company plans the filing of the financial statements under the Basic Disclosure Guidelines for December 31, 2020, before the filing deadline of March 31, 2021.
ENZC IS ABOUT TO GO GREEN AND THEN THE PANIC BUYS AS PREDICTED...
I gotta get in!!
I don't care that the price is climbing!
YOU GOTTA TO BE IN IT TO WIN IT!!
ENZC ENZC ENZC
ENZC is being FUNDED by WHOM?
Don't KNOW
THAT LAST PR WAS YET ANOTHER INFORMATION RELEASE TO SHAREHOLDERS TO LET THEM KNOW THE STATUSES of ENZC TREMENDOUS ENDEAVORS.
THE FLOAT HAS NOT GROWN SINCE OCTOBER 15, 2020
PLUS, THEY WILL KEEP WORKING UNTIL THERE IS a PARTNERSHIP, BUYOUT or MANY MANY LEASING DEALS.
ANOTHER PR ANOTHER day CLOSER to the BIG BANG!!!!!
AND WITH 24 GREEN FLAGS NOW, IT IS ALL SYSTEMS GO GO GO!!!
WHEN THESE BEAUTY GET 24 GREEN FLAGS, IT MIGHT BE TIME TO TAKE ANOTHER LOOK AT THE STATS...OH YEA
What was the stock 5 months ago?
$0.010
What was the stock 4 months ago?
$0.027
What was the stock 3 months ago?
$0.039
What was the stock 2 months ago?
$0.17
What was the stock 1 month ago?
$0.65
So we are trading at one half of what we were trading at just one month ago.
Why?
The stock ran along with the rest of the OTC and then made a correction and has settle $0.30 cent range while even hitting a TEMPORARY low of $0.22 cents along the way.
ENZC will trade in this RANGE until the stock MOVES UP on its next leg.
[b[color=red]]WELCOME TO OTC LAND OF THE PUMP AND DUMP SHARE SELLING SCAMS GOING WILD EVERY DAY[/color] EXCEPT for ENZC
IF THIS ENZC EVER BREAKS .22, IT WILL BE THE BEGINNING of A MASSIVE and I MEAN MASSIVE REVERSAL.
IT'S NOT TOO LATE TO GET IN ON THIS STATE of the ART ZIP CODE CHANGER.
The stock ran along with the rest of the OTC and then made a correction and has settle $0.30 cent range while even hitting a TEMPORARY low of $0.22 cents along the way.
ENZC will trade in this RANGE until the stock MOVES UP on its next leg.
WELCOME TO OTC LAND OF THE PUMP AND DUMP SHARE SELLING SCAMS GOING WILD EVERY DAY EXCEPT for ENZC
IF THIS ENZC EVER BREAKS .22, IT WILL BE THE BEGINNING of A MASSIVE and I MEAN MASSIVE REVERSAL.
IT'S NOT TOO LATE TO GET IN ON THIS STATE of the ART ZIP CODE CHANGER .
ENZC will have its day in court or should I say its day at the TRACK so it can RUN RUN RUN!!!
Some of the Most Successful BIOTECHS Penny Stocks RUNS in History
Will ENZC RUN challange these companies runs?
Don't Know however I will be here to find out.
Axsome Therapeutics Inc. (NASDAQ: AXSM)
Axsome Therapeutics Inc. is a U.S.-based therapeutics company that gained 3,812% throughout 2019 and into 2020.
We can link its 2019 success to its trial of a new drug. In this case, it was AXS-05, a treatment for major depressive disorders.
But, that’s not all…
In late 2019, the FDA also awarded a breakthrough Therapy Designation to AXS-05.
AXSM started January 2019 trading for less than $10 per share. By January 2020, AXSM hit highs of over $100 per share. And in October 2020, it traded around $70 per share.
Provention Bio Inc. (NASDAQ: PRVB)
In the biotech sector, Provention Bio is a ‘penny stock poster child.’
PRVB had big news with its Phase 3 drug trial that could potentially delay or even prevent type 1 diabetes.
This stock has more than tripled from November 2018. And yet there still seem to be market murmurs that it’s underestimated.
We’ve all heard that before…
PRVB started January 2019 trading at $2.55 , and by December 2019, it was trading at $14.97.
By July 2020, PVRB hit a new all-time high trading at $17 per share.
Mylan N.V. (NASDAQ: MYL)
MYL is a pharmaceutical company worth over $8 billion today. The lows on the chart below are just under $6 per share, not technically a penny stock.
But this move is impressive. Runs from $6 to over $70 per share don’t happen often. I’d still consider this an example of a successful penny stock.
Novavax Inc. (NASDAQ: NVAX)
I saved one of the most successful penny stocks for last. NVAX had a huge run this year.
This pharma play ripped from$3.54 at its low to over $331 per share at its highs — all in under a year, thanks to the crazy volatility of the coronavirus market.
Sound Management
In real estate, it’s all about “location, location, location." For penny stocks, it’s about “management, management, management." Sound management can turn around a struggling firm and launch a startup to new heights. More importantly, experienced and ethical management that have a vested interest in the company via share ownership can provide investors with a sense of security.
Of course, superstar managers aren't often found working for penny stock companies, but there are a few examples. Take Concur Technologies, which bounced back from its post-tech bubble price of $0.31 and got bought out in 2014 at $129 per share. This remarkable comeback is owed to many factors, but one that stood out was the strong vested interest of President and COO Rajeev Singh. Singh, who had co-founded the company in 1993, filled a plethora of management roles over the firm’s lifespan before he finally stepped down after Concur’s acquisition by software giant SAP SE (SAP).
The Bottom Line
Penny stocks are extremely volatile and speculative by nature. As most trade on OTC exchanges or via pink sheets, where listing standards are lax, penny stocks are susceptible to manipulation and fraud. Still, the potential to make large returns is a strong allure, driving risk-taking investors into taking positions in these securities. Though many penny stocks go bust, if an investor exercises careful fundamental analysis and picks sound management teams, they could find the coveted diamond in the rough.
Makes you wonder WHY ENZC is getting so MUCH ATTENTION from all over the place.
http://denverscientificai.net/
https://aumag.org/2013/09/26/the-future-of-clone-3/
https://www.cameo.com/v/6050d64aaa8f03001dbd6a01
https://www.cameo.com/v/6050e110e4e283001d59bd9f
The only FINANCIALS matter at this point are the PCAOB ones for the years 2019 ad 2020.
ENZC is not making MONEY however they are making PROGRESS that is going to put them in the POSITION to make MONEY in the FUTURE.
Whether the progression that puts ENZC in the POSITION to make MONEY happens tomorrow, next week, next month or next year is an UNKNOWN variable.
That is the BEAUTY of ENZC.
It IS gonna HAPPEN just don't know WHEN.
YE HA
GIDDY UP
ENZC IS ABOUT TO GO GREEN AND THEN THE PANIC BUYS AS PREDICTED...
I gotta get in!!
I don't care that the price is climbing!
YOU GOTTA TO BE IN IT TO WIN IT!!
ENZC ENZC ENZC
ENZC is being FUNDED by WHOM?
Don't KNOW
THAT LAST PR WAS YET ANOTHER INFORMATION RELEASE TO SHAREHOLDERS TO LET THEM KNOW THE STATUSES of ENZC TREMENDOUS ENDEAVORS.
THE FLOAT HAS NOT GROWN SINCE OCTOBER 15, 2020
PLUS, THEY WILL KEEP WORKING UNTIL THERE IS a PARTNERSHIP, BUYOUT or MANY MANY LEASING DEALS.
ANOTHER PR ANOTHER day CLOSER to the BIG BANG!!!!!
AND WITH 24 GREEN FLAGS NOW, IT IS ALL SYSTEMS GO GO GO!!!
WHEN THESE BEAUTY GET 24 GREEN FLAGS, IT MIGHT BE TIME TO TAKE ANOTHER LOOK AT THE STATS...OH YEA
What was the stock 5 months ago?
$0.010
What was the stock 4 months ago?
$0.027
What was the stock 3 months ago?
$0.039
What was the stock 2 months ago?
$0.17
What was the stock 1 month ago?
$0.65
So we are trading at one half of what we were trading at just one month ago.
Why?
The stock ran along with the rest of the OTC and then made a correction and has settle $0.30 cent range while even hitting a TEMPORARY low of $0.22 cents along the way.
ENZC will trade in this RANGE until the stock MOVES UP on its next leg.
WELCOME TO OTC LAND OF THE PUMP AND DUMP SHARE SELLING SCAMS GOING WILD EVERY DAY EXCEPT for ENZC
IF THIS ENZC EVER BREAKS .22, IT WILL BE THE BEGINNING of A MASSIVE and I MEAN MASSIVE REVERSAL.
IT'S NOT TOO LATE TO GET IN ON THIS STATE of the ART ZIP CODE CHANGER .
You don't know if ENZC is going to FAIL.
NOBODY does.
At the PRESENT time ENZC is on TRACK to Succeed.
It may not succeed however the current INFORMATION suggest SUCCESS is on the HORIZON.
He Yah
GIDDY UP
Yes ENZC sold Shares to pay bills for the PAST ventures that didn't pan out.
Now we have the new ENZC that is not selling shares and is getting funding eleswhere.
The new ENZC is a product of the old ENZC plus BioClonetics with CEO Charles Cotropia running things.
It is still a penny stock on the OTC and a very RISKY investment.
Risk versus Reward:
Risk:
1. Technology Fails
2. Not enough funding to continue
3. Trials fails
4. No interest from Big Pharma
5. It is a scam
6. Daily trade volume low
Reward:
1. Technology Succeeds
2. Funding is Sufficient
3. Trials are Successful
4. HUGE interest from Big Pharma
5. It is a Legitimate Developmental Company with a very Bright future
6. Daily trade volume high
Either list could be longer however it would be a moot point.
The question is simple.
Based of the information avaliable which list is more appropriate at the PRESENT time?
Things may change in a week or a month to reflect more RISK than reward
or more REWARD than risk.
Today ENZC is in a REWARD phase.
The only FINANCIALS matter at this point are the PCAOB ones for the years 2019 ad 2020.
ENZC is not making MONEY however they are making PROGRESS that is going to put them in the POSITION to make MONEY in the FUTURE.
Whether the progression that puts ENZC in the POSITION to make MONEY happens tomorrow, next week, next month or next year is an UNKNOWN variable.
That is the BEAUTY of ENZC.
It IS gonna HAPPEN just don't know WHEN.
YE HA
GIDDY UP
ENZC does not have a CURE_ALL drug!!!
ENZC:
Enzolytics, Inc. is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Enzolytics is committed to creating drugs for the better health of mankind.
Enzolytics is a Texas based biotechnology company with both patented anti-HIV therapeutics and a proprietary methodology for producing fully human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The Company has clinically tested its anti-HIV therapeutics known as ITV-1. ITV-1 is a suspension of Inactivated Pepsin Fragment (IPF), a purified extract of porcine pepsin. ITV-1 has been shown to strengthen the immune system and may be used to facilitate a broad range of applications. ITV-1 has been tested in HIV patients in a clinical trial conducted under the strict guidelines of the European Union where it demonstrated beneficial outcomes. Additionally, the Company has created a proprietary cell line that produces fully human monoclonal antibodies that target and neutralize the HIV virus.
The Company’s scientific team, Harry Zhabilov, Joseph Cotropia MD and Gaurav Chandra MD, pioneered the Company’s proprietary therapeutics for treating infectious diseases, including HIV-1, Hepatitis (A, B, C), rabies, influenza A and B, tetanus and diphtheria. The Company’s therapeutics may also be used to treat Rheumatoid Arthritis and certain forms of cancer.
The Company has also pioneered a proprietary method for creating human cell lines that produce fully human monoclonal antibodies directed against many infectious diseases. One antibody (designated as CLONE 3) has been demonstrated in tests in 5 international labs to fully neutralize over 95% of all strains and viral subtypes of HIV-1 against which it has been tested.
These HIV therapeutics may be used as an immunotherapeutic treatment for individuals with HIV/AIDS. They may also be developed for use as a prophylactic and therapeutic vaccine to prevent uninfected populations from contracting the HIV virus. Treatment using the fully human anti-HIV antibody will be far superior to current ARV therapy for several significant reasons: (1) the therapy will be effective and non-toxic, (2) will not require lifetime treatment and (3) will be far less expensive.
Thus, for the patient, immunotherapy will be remarkably different — it will be safer, provide a much-needed immunotherapeutic cure rather than requiring lifelong treatment and costs substantially less than current antiretroviral therapy.
The Company also has created human cell lines that produce human antibodies against other infectious diseases, including rabies, influenza, tetanus and diphtheria. As a part of its mission, the Company is testing these antibodies to prepare them for use as therapies against these diseases.
As a result of the recent acquisition of the biotech company BioClonetics Immunotherapeutics, Inc., Enzolytics is now advancing additional complementary therapeutic platforms for treating infectious diseases, including a focus on production of anti-SARS-CoV-2 (CoronaVirus) monoclonal antibodies to treat COVID-19.
Therapeutic monoclonal antibodies
The biopharmaceutical market, like the global pharmaceutical market, has been expanding every year and is expected to reach approximately 230 billion dollars in 2018, twice the sum in 2010 [1]. It is forecasted to be >380 billion dollars in 2024 [1]. Recombinant proteins, followed by therapeutic antibodies, have been the main contributors to the biopharmaceutical market in the past. However, in 2017 [2] the sales of antibody-based medicines took on the leading position, with expected sales of 172.8 billion dollars in 2022, about 20% of the global pharmaceutical market [2].
It is noteworthy that the range of therapeutic monoclonal antibodies has been remarkably increasing since the late 1990s, the total number approved by the US FDA reaching 64 in 2018 [2,3] (see Table 1 list for those from 2015 to 2017). In 2017, a total of 11 therapeutic monoclonal antibodies were approved. There are interesting changes in the characteristics of the antibodies attracting attention. As shown in Figure 1, the percentage of human and humanized antibodies in the total has dramatically increased. The reasons for continuous expansion of the market for therapeutic antibodies include an increase in the number of approvals, efforts to explore other target diseases for the already approved therapeutic antibodies, as well as improvements in formulations and dosage forms. Finding new target antigens will be of critical importance for further development of antibody-based medicines in the future.64 therapeutic monoclonal antibodies have been approved by the US FDA. The ratio of human and humanized monoclonal antibodies to the total sum of therapeutic monoclonal antibodies is increasing year by year.
Bispecific antibodies [6–10], antibody–drug conjugates [11], sugar chain-modified antibodies [12–15] and low molecular weight antibodies [6,16] are now being emphasized as next-generation products. Some bispecific antibodies and antibody–drug conjugates are already on the market, with emicizumab [17] as an example of the former, and gemtuzumab ozogamicin [18], inotuzumab ozogamicin [19] and brentuximab vedotin [20] featuring in the latter.
There is another important point regarding further development of therapeutic monoclonal antibodies. A critical reason for their employment is their high specificity and affinity for targeted antigens. It is known that monoclonal antibodies can specifically recognize two types of epitopes (Figure 2). One is linear in the primary structures of proteins. The other is conformational, dependent on secondary and tertiary structures. In addition to their primary, secondary and tertiary structures, proteins may also exhibit quarterly structures formed by hetero- or homosubunits, which provide unique interfacial geometries on their complexes. Intact native proteins mainly feature secondary and tertiary structures, but various kinds of monoclonal antibodies do not necessarily have specificity for conformational structures, although they have been raised against a large number of proteinous antigens.
Epitope recognition by antibodies is generally divided into two types. One is linear epitope-specific recognition and the other is conformational or discontinuous epitope specific.
Such specific recognition of conformational structures of proteins would be expected to give more strict selectivity and affinity for therapeutic purposes. Notably, stereo-specific monoclonal antibodies recognizing 3D configurations of molecules, offer advantages over linear epitope-specific monoclonal antibodies, which only recognize 2D configuration. Again we should stress that target antigens for therapy predominantly feature secondary and tertiary structures. Monoclonal antibodies recognizing primary structures can have affinity for only restricted regions in intact antigens, because linear epitopes can be masked by conformational folding. Thus, the employment of stereo-specific monoclonal antibodies should be our goal.
Production of stereo-specific monoclonal antibodies against different proteins
The next point is how to produce stereo-specific monoclonal antibodies. Until very recently, no practical technologies have been available for their generation, because of difficulties like how to immunize a mouse maintaining the structure of the antigen intact in the presence of adjuvant. While adjuvants generally allow more effective sensitization, they usually disrupt the original protein native structure. If an adjuvant is not used, immunization efficiency may be very low. Another difficulty is strict selection of sensitized B lymphocytes secreting stereo-specific monoclonal antibodies. Even when immunization is successful with a native intact antigen, the number of desired sensitized B lymphocytes is usually extremely small, accounting for only a few percent of the total spleen cells after repeated immunization.
However, we have now established an original stereo-specific targeting (SST) technique [21–25]. The protocol promises efficient generation of stereo-specific monoclonal antibodies on the basis of hybridoma technology, as illustrated in Figure 3. One of the critical points is strict selection of the required sensitized B lymphocytes by intact antigens expressed on myeloma cells through B-cell receptors (BCRs). This precise selection also enables efficient formation of B-cell and myeloma-cell complexes for generating hybridoma cells secreting the aimed for antibodies.
https://www.futuremedicine.com/doi/full/10.2217/imt-2018-0130